AbbVie tumbles on drug test disappointment, Bristol-Myers gains
AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor which makes a similar drug, have jumped. Market Domination Hosts Julie Hyman and Josh Lipton outline what investors need to know.
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983 ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Here are two brilliant options along those lines: CVS Health ( CVS 0.44%) and Bristol Myers Squibb ( BMY -1.03%). Find out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback